K
3EE0
vs
D
DAX Index
Over the past 12 months, 3EE0 has underperformed DAX Index, delivering a return of -100% compared to the DAX Index's +13% growth.
Stocks Performance
3EE0 vs DAX Index
Performance Gap
3EE0 vs DAX Index
Performance By Year
3EE0 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kancera AB
Glance View
Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. The company is headquartered in Solna, Stockholm. The company went IPO on 2011-02-21. The firm's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The firm's other activities include development of cancer models and stem cell-based techniques. The firm is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The firm's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
